Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 22545784)

1.

Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles.

Parrott MC, Finniss M, Luft JC, Pandya A, Gullapalli A, Napier ME, DeSimone JM.

J Am Chem Soc. 2012 May 9;134(18):7978-82. doi: 10.1021/ja301710z. Epub 2012 Apr 30.

2.

Co-delivery of 10-hydroxycamptothecin with doxorubicin conjugated prodrugs for enhanced anticancer efficacy.

Zhang Y, Xiao C, Li M, Chen J, Ding J, He C, Zhuang X, Chen X.

Macromol Biosci. 2013 May;13(5):584-94. doi: 10.1002/mabi.201200441. Epub 2013 Feb 18.

PMID:
23420692
3.

Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.

Xiao H, Noble GT, Stefanick JF, Qi R, Kiziltepe T, Jing X, Bilgicer B.

J Control Release. 2014 Jan 10;173:11-7.

PMID:
24511610
4.

A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.

Yuan Z, Yi X, Zhang J, Cheng S, Zhuo R, Li F.

Chem Commun (Camb). 2013 Jan 28;49(8):801-3. doi: 10.1039/c2cc37798e.

PMID:
23235958
5.

Hydrophilic mesoporous carbon nanoparticles as carriers for sustained release of hydrophobic anti-cancer drugs.

Gu J, Su S, Li Y, He Q, Shi J.

Chem Commun (Camb). 2011 Feb 21;47(7):2101-3. doi: 10.1039/c0cc04598e. Epub 2010 Dec 24.

PMID:
21183990
6.

Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.

Zhu S, Lansakara-P DS, Li X, Cui Z.

Bioconjug Chem. 2012 May 16;23(5):966-80. doi: 10.1021/bc2005945. Epub 2012 Apr 18.

7.

Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.

Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA, Peterson JA, Perkins EJ, Pu YJ, Reutzel-Edens SM, Remick DM, Starling JJ, Stephenson GA, Vaid RK, Zhang D, McCarthy JR.

J Med Chem. 2009 Nov 26;52(22):6958-61. doi: 10.1021/jm901181h.

PMID:
19860433
8.

Nanoparticles as delivery carriers for anticancer prodrugs.

Fang JY, Al-Suwayeh SA.

Expert Opin Drug Deliv. 2012 Jun;9(6):657-69. doi: 10.1517/17425247.2012.679927. Epub 2012 Apr 16. Review.

PMID:
22507134
9.

Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy.

Arya G, Vandana M, Acharya S, Sahoo SK.

Nanomedicine. 2011 Dec;7(6):859-70. doi: 10.1016/j.nano.2011.03.009. Epub 2011 Apr 13. Erratum in: Nanomedicine. 2013 May;9(4):580.

PMID:
21550422
10.

Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug.

Maiti S, Park N, Han JH, Jeon HM, Lee JH, Bhuniya S, Kang C, Kim JS.

J Am Chem Soc. 2013 Mar 20;135(11):4567-72. doi: 10.1021/ja401350x. Epub 2013 Mar 12.

PMID:
23461361
11.

Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.

Bildstein L, Dubernet C, Marsaud V, Chacun H, Nicolas V, Gueutin C, Sarasin A, Bénech H, Lepêtre-Mouelhi S, Desmaële D, Couvreur P.

J Control Release. 2010 Oct 15;147(2):163-70. doi: 10.1016/j.jconrel.2010.07.120. Epub 2010 Aug 5.

PMID:
20691740
12.
13.

Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.

Kumar V, Hong SY, Maciag AE, Saavedra JE, Adamson DH, Prud'homme RK, Keefer LK, Chakrapani H.

Mol Pharm. 2010 Feb 1;7(1):291-8. doi: 10.1021/mp900245h.

14.

Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.

Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M, Cattel L.

J Control Release. 2004 Dec 10;100(3):331-46.

PMID:
15567500
15.

[Investigation into the controlled release behavior of gemcitabine-loaded nanovesicles].

Zheng JJ, Jia L, Li H, Huang KH, Shuai XT, Li YY.

Zhonghua Yi Xue Za Zhi. 2008 Jul 22;88(28):2005-7. Chinese.

PMID:
19062746
16.

Production and characterization of gamma-polyglutamic acid nanoparticles for controlled anticancer drug release.

Manocha B, Margaritis A.

Crit Rev Biotechnol. 2008;28(2):83-99. doi: 10.1080/07388550802107483 . Review.

PMID:
18568849
17.

Polymer prodrug nanoparticles based on naturally occurring isoprenoid for anticancer therapy.

Trung Bui D, Maksimenko A, Desmaële D, Harrisson S, Vauthier C, Couvreur P, Nicolas J.

Biomacromolecules. 2013 Aug 12;14(8):2837-47. doi: 10.1021/bm400657g. Epub 2013 Jul 18.

PMID:
23829862
18.

Nanoparticles with in vivo anticancer activity from polymer prodrug amphiphiles prepared by living radical polymerization.

Harrisson S, Nicolas J, Maksimenko A, Bui DT, Mougin J, Couvreur P.

Angew Chem Int Ed Engl. 2013 Feb 4;52(6):1678-82. doi: 10.1002/anie.201207297. Epub 2012 Dec 17. No abstract available.

PMID:
23255475
19.

Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation.

Kiew LV, Cheong SK, Sidik K, Chung LY.

Int J Pharm. 2010 May 31;391(1-2):212-20. doi: 10.1016/j.ijpharm.2010.03.010. Epub 2010 Mar 7.

PMID:
20214970
20.

Development of thermosensitive poly(n-isopropylacrylamide-co-((2-dimethylamino) ethyl methacrylate))-based nanoparticles for controlled drug release.

Peng CL, Tsai HM, Yang SJ, Luo TY, Lin CF, Lin WJ, Shieh MJ.

Nanotechnology. 2011 Jul 1;22(26):265608. doi: 10.1088/0957-4484/22/26/265608. Epub 2011 May 17.

PMID:
21576795
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk